Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions.
The treatment options for patients with advanced prostate cancer are limited. Because of recent advances in the understanding of the molecular biology of prostate cancer, the accessibility of the prostate for injection, and the availability of gene promotors that allow tissue-specific expression of therapeutic gene products, gene therapy for prostate cancer has realized significant achievements in recent years. What once belonged to the realm of basic science is now entering the domain of phase II clinical trials. In this review, current results and future directions in prostate gene therapy at the University of California, Los Angeles, are discussed.
Pantuck
A J
AJ
Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA.
Zisman
A
A
Belldegrun
A S
AS
D002140:California; D017321:Clinical Trials, Phase I as Topic; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011471:Prostatic Neoplasms / Q000628:therapy*